Retrospective analysis of HER2 therapy interruption in patients responding to the treatment in metastatic HER2+ breast cancer

INTRODUCTION: Human epidermal growth factor receptor 2 (HER2)-targeted-therapy regimens can lead to prolonged tumour responses in metastatic HER2+ breast cancer. Clinical trials have concerned use of HER2-targeted agents until disease progression, but it is unknown whether the therapy can be interru...

Descripción completa

Detalles Bibliográficos
Autores principales: Moilanen, Tiina, Mustanoja, Susanna, Karihtala, Peeter, Koivunen, Jussi P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2017
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519805/
https://www.ncbi.nlm.nih.gov/pubmed/28761759
http://dx.doi.org/10.1136/esmoopen-2017-000202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519805/
https://www.ncbi.nlm.nih.gov/pubmed/28761759
http://dx.doi.org/10.1136/esmoopen-2017-000202

Ejemplares similares